Conagra Brands, Inc. · CAG · FY2026 Q2 · Calendar Q4 2025
Conagra Maintains Outlook as Frozen and Snacks Recover
The quarter supports a measured recovery case: management sees second-half organic sales growth and frozen-market-share recovery, while productivity, supply-chain investment and Project Catalyst are intended to support margins. The evidence remains balanced by Q3 absorption pressure, inflation, pricing risk and the impairment charge.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about CAG FY2026 Q2
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management highlighted the launch of Project Catalyst, completion of the new baked chicken facility with planned capacity expansion, and an impairment charge tied to a higher discount rate. Compared with the prior quarter, the focus shifted toward second-half organic sales growth, frozen promotions and absorbing the Ardent shortfall while maintaining the outlook.
Guidance delta
Management maintained its outlook, expecting organic net-sales growth in the second half and expressing confidence it can absorb the Ardent shortfall while remaining within its EPS range.
Key takeaways
- Management expects organic net-sales growth in the second half of FY26.
- Frozen market share has largely been reclaimed, with stronger promotions planned for the back half of FY26.
- Margin expansion is expected from productivity, supply-chain improvements, selective pricing and Project Catalyst.
- Innovation is focused on protein, clean-label and value-oriented products.
- An impairment charge reflected a higher discount rate after a sustained stock-price decline.
Management priorities
- Roll out Project Catalyst during calendar 2026.
- Expand capacity at the baked chicken facility.
- Continue innovation in protein and clean-label products.
- Use productivity initiatives, supply-chain improvements and selective pricing to support margins.
- Prioritize debt reduction in potential portfolio optimization activity.
Follow CAG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Oct 2, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 1, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Oct 1, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Sep 18, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 16, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 16, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jun 5, 2026 |
| Bernstein | Underperform | Market Perform | Downgrade | Jun 3, 2026 |
| Wells Fargo | Underweight | Underweight | Maintain | May 18, 2026 |
| Stifel | Hold | Hold | Maintain | Apr 21, 2026 |
| BNP Paribas | Neutral | Outperform | Downgrade | Apr 9, 2026 |
| Goldman Sachs | Sell | Sell | Maintain | Apr 2, 2026 |
| TD Cowen | Hold | Hold | Maintain | Dec 22, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Dec 22, 2025 |
| Jefferies | Hold | Hold | Maintain | Dec 12, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Jun 28, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Mar 31, 2023 |
| SunTrust Robinson Humphrey | Hold | Buy | Downgrade | May 11, 2020 |
| CFRA | Strong Buy | Buy | Upgrade | Mar 12, 2020 |
| Stifel Nicolaus | Buy | Hold | Upgrade | Oct 30, 2017 |
| Bank of America | Buy | Neutral | Upgrade | Feb 12, 2016 |
| Keybanc | Hold | Buy | Downgrade | Jun 18, 2014 |
| S&P Capital IQ | Buy | Strong Buy | Downgrade | Dec 19, 2013 |
| Edward Jones | Buy | Hold | Upgrade | Dec 13, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $14.92. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $14 | $13.46 | -6.2% | Oct 1, 2026 |
| Evercore ISI | Analyst unavailable | $13 | $14.16 | -12.9% | Sep 29, 2026 |
| Deutsche Bank | Steve Powers | $13 | $15.12 | -12.9% | Sep 18, 2026 |
| Evercore ISI | Analyst unavailable | $12.5 | $14.61 | -16.2% | Sep 14, 2026 |
| UBS | Peter Grom | $14 | $14.44 | -6.2% | Jul 16, 2026 |
| RBC Capital | Analyst unavailable | $14 | $14.28 | -6.2% | Jul 16, 2026 |
| Barclays | Analyst unavailable | $16 | $14.04 | +7.2% | Jul 8, 2026 |
| RBC Capital | Analyst unavailable | $16 | $13.89 | +7.2% | Jun 25, 2026 |
| Deutsche Bank | Steve Powers | $12 | $13.16 | -19.6% | Jun 18, 2026 |
| Morgan Stanley | Megan Alexander Clapp | $13 | $12.66 | -12.9% | Jun 5, 2026 |
| Coker Palmer | Thomas Palmer | $14 | $12.66 | -6.2% | Jun 5, 2026 |
| Bernstein | Analyst unavailable | $12 | $12.86 | -19.6% | Jun 3, 2026 |
| UBS | Peter Grom | $13 | $12.92 | -12.9% | Jun 2, 2026 |
| Morgan Stanley | Megan Alexander Clapp | $15 | $14.53 | +0.5% | Apr 23, 2026 |
| Stifel Nicolaus | Analyst unavailable | $15 | $14.84 | +0.5% | Apr 21, 2026 |
| BNP Paribas | Analyst unavailable | $16 | $15.55 | +7.2% | Apr 9, 2026 |
| Wells Fargo | Chris Carey | $15 | $16.98 | +0.5% | Mar 12, 2026 |
| UBS | Analyst unavailable | $20 | $19.52 | +34.0% | Feb 13, 2026 |
| Morgan Stanley | Megan Alexander Clapp | $18 | $17.38 | +20.6% | Jan 16, 2026 |
| Wells Fargo | Analyst unavailable | $18 | $17.05 | +20.6% | Jan 5, 2026 |
| Bernstein | Alexia Howard | $18 | $17.48 | +20.6% | Dec 29, 2025 |
| UBS | Peter Grom | $18 | $17.26 | +20.6% | Dec 23, 2025 |
| Deutsche Bank | Steve Powers | $18 | $17.3 | +20.6% | Dec 22, 2025 |
| Morgan Stanley | Analyst unavailable | $19 | $17.36 | +27.3% | Dec 22, 2025 |
| Evercore ISI | David Palmer | $22 | $17.36 | +47.5% | Dec 22, 2025 |
| RBC Capital | Analyst unavailable | $20 | $17.35 | +34.0% | Dec 22, 2025 |
| RBC Capital | Nik Modi | $22 | $17.74 | +47.5% | Dec 17, 2025 |
| Wells Fargo | Analyst unavailable | $19 | $17.83 | +27.3% | Dec 12, 2025 |
| Jefferies | Analyst unavailable | $18 | $17.6 | +20.6% | Dec 11, 2025 |
| Stifel Nicolaus | Analyst unavailable | $19 | $17.44 | +27.3% | Dec 11, 2025 |
| Goldman Sachs | Analyst unavailable | $16 | $17.52 | +7.2% | Nov 25, 2025 |
| Wells Fargo | Chris Carey | $20 | $19.3 | +34.0% | Oct 2, 2025 |
| Morgan Stanley | Megan Alexander Clapp | $20 | $19.4 | +34.0% | Jul 11, 2025 |
| Bernstein | Alexia Howard | $21 | $19.4 | +40.8% | Jul 11, 2025 |
| Morgan Stanley | Megan Alexander | $22 | $20.52 | +47.5% | Jul 7, 2025 |
| Evercore ISI | David Palmer | $26 | $20.99 | +74.3% | Jul 7, 2025 |
| Jefferies | Rob Dickerson | $30 | $32.31 | +101.1% | Sep 24, 2024 |
| Coker Palmer | Thomas Palmer | $33 | $32.31 | +121.2% | Sep 24, 2024 |
| Goldman Sachs | Leah Jordan | $36 | $29.82 | +141.3% | Aug 12, 2024 |
| Stifel Nicolaus | Matthew Smith | $30 | $28.38 | +101.1% | Jul 12, 2024 |
| Barclays | Andrew Lazar | $34 | $31.09 | +127.9% | Apr 8, 2024 |
| Wells Fargo | Chris Carey | $32 | $30.64 | +114.5% | Apr 5, 2024 |
| Stifel Nicolaus | Matthew Smith | $32 | $30.64 | +114.5% | Apr 5, 2024 |
| Coker Palmer | Thomas Palmer | $32 | $30.64 | +114.5% | Apr 5, 2024 |
| Morgan Stanley | Pamela Kaufman | $32 | $30.64 | +114.5% | Apr 5, 2024 |
| CFRA | Arun Sundaram | $34 | $30.64 | +127.9% | Apr 4, 2024 |
| Evercore ISI | David Palmer | $32 | $29.06 | +114.5% | Apr 4, 2024 |
| RBC Capital | Nik Modi | $29 | $29.58 | +94.4% | Apr 1, 2024 |
| Stifel Nicolaus | Matthew Smith | $43 | $35.96 | +188.2% | May 19, 2023 |
| Deutsche Bank | Steve Powers | $35 | $35.52 | +134.6% | Mar 20, 2023 |
| RBC Capital | Conagra Brands | $38 | $40.58 | +154.7% | Jan 6, 2023 |
| J.P. Morgan | Analyst unavailable | $43 | $41 | +188.2% | Jan 6, 2023 |
| Morgan Stanley | Analyst unavailable | $48 | $40.5 | +221.7% | Jan 6, 2023 |
| UBS | Analyst unavailable | $45 | $40.66 | +201.6% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $40 | $39.97 | +168.1% | Jan 6, 2023 |
| Evercore ISI | Analyst unavailable | $42 | $38.77 | +181.5% | Dec 29, 2022 |
| Morgan Stanley | Pamela Kaufman | $45 | $38.49 | +201.6% | Dec 20, 2022 |
| Deutsche Bank | Steve Powers | $34 | $38.25 | +127.9% | Dec 6, 2022 |
| UBS | Cody Ross | $41 | $35.81 | +174.8% | Nov 18, 2022 |
| BNP Paribas | Analyst unavailable | $42 | $33.91 | +181.5% | Nov 15, 2022 |
| Morgan Stanley | Pamela Kaufman | $34 | $33.83 | +127.9% | Jul 15, 2022 |
| Morgan Stanley | Pamela Kaufman | $36 | $35.11 | +141.3% | Jan 14, 2022 |
| Citigroup | Wendy Nicholson | $37 | $32.96 | +148.0% | Jul 14, 2021 |
| Stifel Nicolaus | Christopher Growe | $35 | $32.96 | +134.6% | Jul 14, 2021 |
| Barclays | Andrew Lazar | $39 | $32.96 | +161.4% | Jul 14, 2021 |
Track every rating change on CAG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationConagra Brands, Inc., a prominent manufacturer of packaged food products, conducts its business across North America through its various subsidiary companies. The firm organizes its extensive operations into four distinct segments: Grocery & Snacks, Refrigerated & Frozen, International, and Foodservice. The Grocery & Snacks division primarily distributes non-perishable food items through various retail channels within the United States. In contrast, the Refrigerated & Frozen segment focuses on supplying temperature-sensitive food products to comparable U.S. retail outlets.…
Historical context
All CAG earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BJ BJ's Wholesale Club Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.0% | BJ’s Q3 guidance rises, but one-time benefit clouds run rate |
| WMT Walmart Inc. | FY2027 Q3 · Calendar Q4 2026 | +1.9% | -1.0% | Walmart raises FY2027 outlook as e-commerce, ads and membership grow |
| TGT Target Corporation | FY2026 Q3 · Calendar Q4 2026 | +29.3% | +4.0% | Target’s Q3 rebound lifts outlook, while home and apparel remain weak spots |
| TSN Tyson Foods, Inc. | FY2026 Q4 · Calendar Q4 2026 | +14.4% | +8.7% | Tyson’s FY2027 plan pairs lower sales with continued operating investment |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the CAG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-28T20:20:57.835484+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-28T20:20:57.832534+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-28. For educational purposes only; not investment advice.